[Beclomethasonedipropionate for corticoid inhalation therapy in bronchial asthma].
Beclomethasone dipropionate, a new corticosteroid for inhalation in the form of a pressurised aerosol with a daily dosage of 300-400/mug, has been given to 130 adult asthmatics. In 56% of the steroid-dependent asthmatics, oral or parenteral corticosteroids were reduced and in a further 28% discontinued entirely. In 16% of patients a reduction of systemic corticosteroids could not be achieved. 12 patients suffering from an obstructive airway disease who had not previously been on systemic corticosteroids were treated successfully with inhalation of beclomethasone dipropionate alone. The reduced dosage of systemic corticosteroids as a result of the use of beclomethasone dipropionate was 4.24 mg of prednisone daily. Side effects, in the form of mouth candidiasis, were noted in only 2 patients.
D000328:Adult; D001249:Asthma / Q000188:drug therapy*; D001507:Beclomethasone / Q000592:standards* / Q000627:therapeutic use; D004341:Drug Evaluation; D006801:Humans; D008775:Methylprednisolone / Q000031:analogs & derivatives*; D012138:Respiratory Therapy
D001507:Beclomethasone; D008775:Methylprednisolone
Belcomethasondipropionat zur inhalativen Corticoidbehandlung des Bronchealasthmas